These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15198554)

  • 21. Real-time monitoring of changes of adsorbed and crystalline water contents in tablet formulation powder containing theophylline anhydrate at various temperatures during agitated granulation by near-infrared spectroscopy.
    Otsuka M; Kanai Y; Hattori Y
    J Pharm Sci; 2014 Sep; 103(9):2924-2936. PubMed ID: 24832393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of drug physical form during granulation, tabletting and storage.
    Williams AC; Cooper VB; Thomas L; Griffith LJ; Petts CR; Booth SW
    Int J Pharm; 2004 May; 275(1-2):29-39. PubMed ID: 15081136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of API concentration on the roller compaction process: modeling and prediction of the post compacted ribbon, granule and tablet properties using multivariate data analysis.
    Boersen N; Carvajal MT; Morris KR; Peck GE; Pinal R
    Drug Dev Ind Pharm; 2015; 41(9):1470-8. PubMed ID: 25212638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of moisture content, temperature and exposure time on the physical stability of chitosan powder and tablets.
    Viljoen JM; Steenekamp JH; Marais AF; Kotzé AF
    Drug Dev Ind Pharm; 2014 Jun; 40(6):730-42. PubMed ID: 23596972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of low levels of amorphous content in inhalation grade lactose by moisture sorption isotherms.
    Vollenbroek J; Hebbink GA; Ziffels S; Steckel H
    Int J Pharm; 2010 Aug; 395(1-2):62-70. PubMed ID: 20493937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fast and non-destructive pore structure analysis using terahertz time-domain spectroscopy.
    Markl D; Bawuah P; Ridgway C; van den Ban S; Goodwin DJ; Ketolainen J; Gane P; Peiponen KE; Zeitler JA
    Int J Pharm; 2018 Feb; 537(1-2):102-110. PubMed ID: 29247699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanical properties of excipients do not affect polymer matrix formation.
    Chatterjee L; Rades T; Tucker IG
    Int J Pharm; 2010 Jan; 384(1-2):87-92. PubMed ID: 19819317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a rapidly dispersing tablet of a poorly wettable compound: formulation DOE and mechanistic study of effect of formulation excipients on wetting of celecoxib.
    He X; Barone MR; Marsac PJ; Sperry DC
    Int J Pharm; 2008 Apr; 353(1-2):176-86. PubMed ID: 18207339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Particle Engineering of Excipients for Direct Compression: Understanding the Role of Material Properties.
    Mangal S; Meiser F; Morton D; Larson I
    Curr Pharm Des; 2015; 21(40):5877-89. PubMed ID: 26446468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The use of natural and synthetic hydrophilic polymers in the formulation of metformin hydrochloride tablets with different profile release].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(3-4):167-84. PubMed ID: 23457958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new formulation for orally disintegrating tablets using a suspension spray-coating method.
    Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
    Int J Pharm; 2009 Dec; 382(1-2):80-7. PubMed ID: 19686825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting orally disintegrating tablets formulations of ibuprophen tablets: an application of the new SeDeM-ODT expert system.
    Aguilar-Díaz JE; García-Montoya E; Suñe-Negre JM; Pérez-Lozano P; Miñarro M; Ticó JR
    Eur J Pharm Biopharm; 2012 Apr; 80(3):638-48. PubMed ID: 22245156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.
    Tahvanainen M; Rotko T; Mäkilä E; Santos HA; Neves D; Laaksonen T; Kallonen A; Hämäläinen K; Peura M; Serimaa R; Salonen J; Hirvonen J; Peltonen L
    Int J Pharm; 2012 Jan; 422(1-2):125-31. PubMed ID: 22063301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of melt granulation technology to enhance tabletting properties of poorly compactible high-dose drugs.
    Lakshman JP; Kowalski J; Vasanthavada M; Tong WQ; Joshi YM; Serajuddin AT
    J Pharm Sci; 2011 Apr; 100(4):1553-65. PubMed ID: 24081475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer.
    Badawy SI; Lee TJ; Menning MM
    AAPS PharmSciTech; 2000 Nov; 1(4):E33. PubMed ID: 14727898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative Humidity Cycling: Implications on the Stability of Moisture-Sensitive Drugs in Solid Pharmaceutical Products.
    Veronica N; Heng PWS; Liew CV
    Mol Pharm; 2023 Feb; 20(2):1072-1085. PubMed ID: 36480246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets.
    Pabari RM; Ramtoola Z
    Int J Pharm; 2012 Jul; 430(1-2):18-25. PubMed ID: 22465631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of the critical points and the role of the pores and viscosity in carbamazepine hydrophilic matrix tablets.
    Aguilar-de-Leyva A; Cifuentes C; Rajabi-Siahboomi AR; Caraballo I
    Eur J Pharm Biopharm; 2012 Jan; 80(1):136-42. PubMed ID: 21946473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of moisture sorption by tablet cores containing superdisintegrants during the aqueous film coating process.
    Pourkavoos N; Peck GE
    Pharm Res; 1993 Aug; 10(8):1212-8. PubMed ID: 8415410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound.
    Menning MM; Dalziel SM
    Mol Pharm; 2013 Nov; 10(11):4005-15. PubMed ID: 23941629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.